Highest-materiality recent filing
CytomX and Regeneron expand collaboration; CytomX to receive $37M in target nomination payments
Amendment No. 4 adds up to eight new collaboration programs; Regeneron nominates first two.
CytomX Q1 rev $10.3M; cash $346.7M; Varseta-M dose optimization enrollment complete (40 pts)
Q1 revenue $10.3M vs $50.9M YoY; decrease driven by completion of BMS and Amgen collaborations.
CytomX closes public offering of ~47M shares/warrants, net proceeds ~$234.4M for pipeline
Sold 45,990,567 shares at $5.30 and pre-funded warrants for 1,179,245 shares at $5.29999 each.
CytomX reports 2025 revenue $76.2M, down 45% YoY; cash $137.1M; Astellas collaboration ends
Revenue $76.2M (down from $138.1M in 2024) on completion of BMS collaboration and lower collaboration milestones.
CytomX Q3 2025 revenue $6.0M (down 82% YoY); cash $143.6M; pipeline on track for key milestones
Total revenue $6.0M in Q3 2025 vs $33.4M in Q3 2024; cash, equivalents and investments $143.6M, runway to Q2 2027.
CytomX reports Grade 5 adverse event in CX-2051 Phase 1 trial; FDA notified, study continues
Single Grade 5 acute kidney injury occurred in patient with solitary kidney; event believed secondary to nausea, vomiting, diarrhea.
CytomX Q2 2025 cash $158.1M; positive CX-2051 Phase 1 data; $100M offering closed
Revenue $18.7M in Q2 2025 vs $25.1M in Q2 2024; operating expenses fell to $19.9M from $33.6M.
CytomX stockholders approve amended equity plan adding 4.38M shares; three directors elected
Stockholders elected three Class I directors: Sean McCarthy (16.4M for), Mani Mohindru (19.7M for), Zhen Su (19.7M for), terms until 2028.
CytomX nets $93.4M in underwritten common stock offering; 76.9M shares at $1.30
Sold 76,923,076 shares of common stock at $1.30/share, generating ~$93.4M in net proceeds after underwriting discounts and expenses.
CytomX Q1 revenue $50.9M; CX-2051 Phase 1 shows 28% ORR in advanced CRC
Q1 revenue $50.9M (up from $41.5M); operating expense $28.3M; cash $79.9M.
Revenue $138.1M for FY2024 vs $101.2M in FY2023 (+36%); cash and investments $100.6M vs $174.5M at year-end.
CytomX receives Nasdaq delisting notice for bid price non-compliance
Nasdaq notified CytomX on Feb 24, 2025 that common stock bid price stayed below $1.00 for 30 consecutive business days through Feb 21, 2025.
CytomX to cut ~40% of workforce, focus on CX-2051, extend cash runway
Workforce reduction of ~40%, primarily affecting G&A and non-partnered research staff, substantially complete in Q1 2025.
CytomX Q2 2024 cash $137.2M; revenue $25.1M; CX-904 update expected by year-end
Cash, equivalents and investments $137.2M at June 30, 2024, down from $150.3M at March 31, 2024.
CytomX Therapeutics appoints Chris Ogden as CFO effective June 15, 2024
Chris Ogden promoted from SVP Finance & Accounting to CFO, effective June 15, 2024.
CytomX Q1 revenue $41.5M, up 77% YoY; positive early CX-904 data
Q1 revenue $41.5M vs $23.5M YoY; cash $150.3M at Mar 31, 2024.
CytomX reports positive Phase 1a data for CX-904: no CRS, 33% response rate in pancreatic cancer
CX-904 demonstrated favorable safety: no CRS of any grade in step-dosing; no Grade >1 CRS overall.
FY2023 revenue $101.2M (up from $53.2M in 2022); operating expenses $107.7M (down from $154.5M).
On January 30, 2025, Jeffrey Landau, Senior Vice President, Chief Business Officer, and Head of Strategy, of CytomX Therapeutics, Inc. (the “Company”) and the Company agreed that Mr. Landau’s employment by the Company would terminate, effective February 7, 2025.
On June 12, 2024, CytomX Therapeutics, Inc. (the “Company”) appointed Chris Ogden to serve as the Company’s Chief Financial Officer effective June 15, 2024 (the “Effective Date”).
On March 20, 2024, Zhen Su, M.D., M.B.A., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective March 20, 2024, as a Class I director, with an initial term expiring at the Company’s 2025 annual meeting of stockholders, filling a vacancy.
Max materiality 0.80 · Median 0.65 · Most common event earnings